In another clinical trial, Souweidane et al. used CED to safely infuse a murine monoclonal antibody targeting glioma-associated B7-H3 antigen, conjugated to the radioisotope conjugate ([124I]-8H9) into the brainstem of pediatric patients with H3K27M-mutant DMG [72]. The gene discussed is CD276; the disease is central nervous system cancer.